Moody's: Operating Headwinds Weigh On Teva's 2017 Deleveraging Plans -- A Credit Negative
New York, January 09, 2017-- Moody's Investors Service commented that Teva Pharmaceutical Industries Ltd's US generics business faces significant headwinds in 2017 including pricing erosion and delays in new launches, a credit negative. This will weigh on the company's ability to delever following the $40 billion Actavis Generics acquisition in August 2016. This is credit negative for Teva given its elevated financial leverage and other business pressures.
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.